NeuBase Therapeutics shares are trading higher after the company reported a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.
Portfolio Pulse from Benzinga Newsdesk
NeuBase Therapeutics reported positive preclinical safety and efficiency data for its Stealth Editors development program, demonstrating gene editing with a non-immunogenic system.
May 22, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuBase Therapeutics shares are trading higher after positive preclinical data for its Stealth Editors development program.
The positive preclinical data for NeuBase Therapeutics' Stealth Editors development program demonstrates the potential of their gene editing technology. This news is likely to boost investor confidence in the company's prospects, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100